SPY752.56+0.35%QQQ679.24+0.66%BTC/USD73,566.43−0.18%DIA523.25+0.29%GLD369.45+0.02%TLT80.86−0.02%

Premium Services

NextCure Inc

NXTCNASDAQ

Trade with Public

Trade with Public

$5.98

-0.29-4.63%

Last update: Nov 10, 4:05 PM

Overview News Charts Earnings Forecast EventsPrice TargetsFinancials Sentiment Ownership Compare Stock Report

Connect With Us

About Benzinga

Market Resources

Advanced Stock Screener Tools
Options Trading Chain Analysis
Comprehensive Earnings Calendar
Dividend Investor Calendar and Alerts
Economic Calendar and Market Events
IPO Calendar and New Listings
Market Outlook and Analysis
Wall Street Analyst Ratings and Targets

Trading Tools & Education

Ring the Bell

© 2026 Benzinga | All Rights Reserved

NextCure (NXTC) Stock Price Target 2026

The average analyst price target for NextCure is $28.40, 391.3% above the current price. Of 5 analysts, 5 rate it Buy. Targets range from $15 to $48. The latest change came on May 11, 2026, when LUCID CAPITAL MARKETS initiated coverage of NextCure with a Buy rating and a $25 price target.

The Average Analyst Price Target for NextCure is $28.40.

Price Target Range — 9 Quarters

Analyst Consensus — 5 Analysts

5Buy

Consensus RatingBuy# Analysts5Avg. Consensus PT$28.40Upside to Avg. PT+391.3%

Rating Trend — Last 9 Months

Latest Upgrades and Downgrades for NextCure Stock

See all ratings →

Date	Firm	Analyst	Action	Rating Change	Price Target
May 11, 2026	LUCID CAPITAL MARKETS	Christopher Liu	Initiate	Buy	$25
Nov 7, 2025	Ladenburg Thalmann	Kevin DeGeeter	Upgrade	Neutral→Buy	$18
Jul 15, 2025	Piper Sandler	Edward Tenthoff	PT Cut	Overweight	$36→$15
Jul 1, 2025	HC Wainwright & Co.	Emily Bodnar	Maintained	Buy	$36
Mar 17, 2025	HC Wainwright & Co.	Emily Bodnar	Maintained	Buy	$36
Mar 7, 2025	HC Wainwright & Co.	Emily Bodnar	PT Cut	Buy	$48→$36
Nov 11, 2024	HC Wainwright & Co.	Emily Bodnar	PT Cut	Buy	$96→$48
Aug 2, 2024	Needham	Gil Blum	Maintained	Buy	$48
Jun 3, 2024	HC Wainwright & Co.	Emily Bodnar	Maintained	Buy	$96
May 31, 2024	HC Wainwright & Co.	Emily Bodnar	Maintained	Buy	$96
May 3, 2024	HC Wainwright & Co.	Emily Bodnar	Maintained	Buy	$96
May 3, 2024	Needham	Gil Blum	Maintained	Buy	$48
Mar 22, 2024	HC Wainwright & Co.	Emily Bodnar	PT Raise	Buy	$60→$96
Mar 20, 2024	Needham	Gil Blum	Maintained	Buy	$48
Dec 14, 2023	Needham	Gil Blum	PT Cut	Buy	$72→$48

Analyst Ratings News

PRO
LUCID CAPITAL MARKETS Initiates Coverage On NextCure with Buy Rating, Announces Price Target of $25

LUCID CAPITAL MARKETS analyst Christopher Liu initiates coverage on NextCure (NASDAQ:NXTC) with a Buy rating and announces Price Target of $25.

Benzinga Newsdesk

PRO
Ladenburg Thalmann Upgrades NextCure to Buy, Announces $18 Price Target

Ladenburg Thalmann analyst Kevin DeGeeter upgrades NextCure (NASDAQ:NXTC) from Neutral to Buy and announces $18 price target.

Benzinga Newsdesk

PRO
Piper Sandler Maintains Overweight on NextCure, Lowers Price Target to $15

Piper Sandler analyst Edward Tenthoff maintains NextCure (NASDAQ:NXTC) with a Overweight and lowers the price target from $36 to $15.

Benzinga Newsdesk

PRO
HC Wainwright & Co. Reiterates Buy on NextCure, Maintains $3 Price Target

HC Wainwright & Co. analyst Emily Bodnar reiterates NextCure (NASDAQ:NXTC) with a Buy and maintains $3 price target.

Benzinga Newsdesk

PRO
HC Wainwright & Co. Reiterates Buy on NextCure, Lowers Price Target to $3

HC Wainwright & Co. analyst Emily Bodnar reiterates NextCure (NASDAQ:NXTC) with a Buy and lowers the price target from $4 to $3.

Benzinga Newsdesk

PRO
HC Wainwright & Co. Maintains Buy on NextCure, Lowers Price Target to $4

HC Wainwright & Co. analyst Emily Bodnar maintains NextCure (NASDAQ:NXTC) with a Buy and lowers the price target from $8 to $4.

Benzinga Newsdesk